Welcome to our dedicated page for Avanos Medical news (Ticker: AVNS), a resource for investors and traders seeking the latest updates and insights on Avanos Medical stock.
Avanos Medical, Inc. reports developments as a medical technology company that develops, manufactures and markets medical device solutions for Specialty Nutrition Systems and Pain Management and Recovery. Its news commonly covers operating results, segment growth, enteral feeding products, non-opioid surgical pain and recovery products, infusion pumps, radiofrequency ablation solutions and cryo-pneumatic compression systems.
Company updates also include Medicare payment and regulatory reimbursement developments for ON-Q, AmbIT and Game Ready, collaborations for outpatient and interventional pain workflows, investor conference presentations, cost and transformation initiatives, and governance matters such as board nominations and shareholder agreements.
Avanos Medical, Inc. (NYSE: AVNS) reported its Q2 2022 results, with net sales of $203 million, a 9% increase year-over-year. Gross margin improved significantly, reaching 57% compared to 46% a year ago. However, net income dropped to $11 million from $38 million in the prior year. The company generated free cash flow of $23 million, up from $10 million last year. Despite supply chain challenges, Avanos expects full-year sales between $815 million and $835 million, projecting adjusted diluted EPS between $1.45 and $1.65.
Avanos Medical, Inc. (NYSE: AVNS) will host a conference call on August 9, 2022, at 9 a.m. ET, to discuss its second-quarter financial results and business highlights. The company will release its financial results before the market opens on the same day. The call will be led by CEO Joe Woody and CFO Michael Greiner. Interested parties can join the call by dialing 877-240-5772 within the U.S. A replay will be available starting August 10 at noon ET. Avanos focuses on innovative medical devices aimed at improving recovery and reducing opioid use.
Avanos Medical, a medical technology company, announced that Michael Greiner, CFO, will participate in a fireside chat at the UBS 2022 Global Healthcare Conference on May 23 at 1:15 p.m. ET. The conference will be accessible via a webcast on Avanos' Investors section of their website, where it will also be archived. Avanos is dedicated to developing breakthrough medical device solutions and operates in over 90 countries, aiming to enhance patient recovery while minimizing opioid use.
Avanos Medical reported a 9% increase in net sales for Q1 2022, totaling $197 million compared to last year. Net income rose to $6 million from a $8 million loss, with adjusted earnings per share at $0.26. The recent acquisition of OrthogenRx contributed positively, and gross margins improved to 54% despite ongoing economic challenges. The company anticipates annual sales between $830 million and $850 million, with adjusted EPS projected at $1.55 to $1.75.
Avanos Medical, Inc. (NYSE: AVNS) will hold a conference call on May 4, 2022, at 9 a.m. ET to discuss its first-quarter 2022 financial results and business highlights. A news release will precede the call, detailing the results. The call will be hosted by CEO Joe Woody and CFO Michael Greiner. Interested parties can join the live call by dialing 877-240-5772 in the U.S. or access the webcast via the Avanos Medical website. A replay will be available later the same day.
Avanos Medical (NYSE: AVNS) will participate in an analyst-led fireside chat at the KeyBanc 2022 Life Sciences & MedTech Investor Forum on March 22, 2022, at approximately 9:45 a.m. ET. CEO Joe Woody and CFO Michael Greiner will present insights into the company's operations and growth strategies. A webcast of the presentation will be available on the Investors section of the Avanos Medical website. The company, headquartered in Alpharetta, Georgia, aims to deliver innovative medical device solutions to enhance patient recovery.
Avanos Medical reported a strong performance for Q4 and full-year 2021 despite COVID-19 challenges. Q4 net sales rose 5% to $193 million, with full-year sales increasing 4% to $745 million. The company achieved a diluted EPS of $0.21 in Q4, compared to a loss last year, and adjusted EPS rose to $0.46. Free cash flow improved significantly, totaling $66 million for 2021. The acquisition of OrthogenRx was completed, enhancing its market presence. For 2022, Avanos expects net sales between $830 million and $850 million, amid ongoing supply chain challenges.
Avanos Medical, Inc. (NYSE: AVNS) will hold a conference call on Feb. 23, 2022, at 9 a.m. ET, to discuss its fourth quarter and full year 2021 financial results. A news release with these results will be issued before the market opens on that day. The call will be led by CEO Joe Woody and CFO Michael Greiner. Participants can access the call by dialing 877-240-5772 in the U.S., with a webcast available through the company’s investor website. A replay will be accessible later that day and for one week following the call.
Avanos Medical (NYSE: AVNS) announced that CEO Joe Woody will present at the 40th Annual J.P. Morgan Healthcare Conference on Jan. 11, 2022, at 10:30 a.m. ET. The presentation will be available via webcast on the Investors section of Avanos' website and will be archived there for later access. Avanos Medical, based in Alpharetta, Georgia, focuses on developing breakthrough medical devices aimed at improving patient outcomes and reducing opioid use during recovery from surgery. For more details, visit www.avanos.com.
Avanos Medical has announced a share repurchase program, allowing the company to buy back up to $30 million of its common stock over a twelve-month period. This initiative, approved by the Board of Directors, aims to enhance shareholder value using existing cash or future cash flows. The buyback will be executed under a Rule 10b5-1 plan that sets specific price, volume, and timing restrictions. CEO Joe Woody expressed confidence in the company's strategy and financial health, emphasizing the prudent investment in the company's stock.